Research programme: sphingosine 1 phosphate 1 receptor agonists - Exelixis/Boehringer Ingelheim
Latest Information Update: 04 Nov 2017
At a glance
- Originator Boehringer Ingelheim; Exelixis
- Class
- Mechanism of Action Sphingosine 1 phosphate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Autoimmune-disorders in Germany
- 04 Nov 2017 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 22 Feb 2011 Early research is ongoing in US and Germany